 |
|
|
|
 |
|
|
| Article 1 to 6 out of 6 concerning Solvay Pharmaceuticals SA
|
-
Abbott to Acquire Solvay Pharmaceuticals Business
(01 Oct 2009)
Diversifies Abbott's pharmaceutical products, expanding international growth platform
Abbott announced a definitive agreement with the Solvay Group for Abbott to acquire Solvay's pharmaceuticals business for EUR 4.5 billion(US$6.6 billion) in cash, providing Abbott with a large and complementary portfolio of pharmaceutical products ...
-
MediGene Signs Agreement with Solvay for the Commercialization of Veregen in Germany, Austria, and Switzerland
(30 Sep 2009)
MediGene AG has signed a license and supply agreement with Solvay Arzneimittel GmbH, the German affiliate of Solvay Pharmaceuticals (Solvay) for the supply and commercialization of VeregenŽ (formerly Polyphenon EŽ ointment) in Germany, Austria, and ...
-
Solvay Group holds 93.1% of Innogenetics shares
(20 Oct 2008)
Offer on Innogenetics shares is extended from 22 October to 12 November
Solvay Pharmaceuticals S.A., a subsidiary of the Solvay Group announced that it will acquire 2,714,371 additional shares of Innogenetics N.V. in a cash transaction valued at EUR 6.5 per share, representing EUR 200.7 million for 100% of the ...
-
Solvay Pharmaceuticals acquires Innogenetics
(11 Sep 2008)
Solvay Group holds 84.3% of Innogenetics shares
Solvay Pharmaceuticals S.A., a subsidiary of the Solvay Group, announced that it succeeded to acquire Innogenetics N.V. in a cash transaction valued at EUR 6.5 per share, representing EUR 200.7 million for 100% of the Innogenetics shares. The offer ...
-
Solvay Pharmaceuticals S.A. launches friendly bid to acquire Innogenetics
(29 Apr 2008)
Building on a successful R&D co-operation
Solvay Pharmaceuticals S.A., a subsidiary of Solvay, and Innogenetics N.V. jointly announced that Solvay Pharmaceuticals S.A. will make a conditional tender offer to acquire Innogenetics in a cash transaction valued at EUR 5.75 per share.Solvay ...
-
Innogenetics and Solvay Pharmaceuticals extend collaboration for biomarker discovery
(10 Apr 2008)
Innogenetics announced a 2-year extension of its longstanding research collaboration with Solvay Pharmaceuticals. Since November 1997, Solvay and Innogenetics have collaborated on a joint research program to explore new targets for Solvay's drug ...
Additional information
Solvay Pharmaceuticals SA
Brussels, Belgium
Company
|
|
|
|
|
|
Top
